Journal of the National Cancer Institute logo Oxford University Press logo

JNCI - Journal of the National Cancer Institute publishes peer-reviewed original research from around the world and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. For the past several years, the JNCI has been ranked as the most-cited original-research cancer journal by the Institute of Scientific Information in its annual Journal Citation Reports. The Journal of the National Cancer Institute's impact factor for 2005, as reported in 2006, was 15.171.

Publisher: Oxford University Press

Volume 96, Number 19, 6 October 2004
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

< previous issue | next issue > | all issues

Press Release
pp. 1407-1407(1)
Author: Sarah L. Zielinski

Press Release
pp. 1407-1407(1)
Author: Sarah L. Zielinski

Outcome Prediction and the Future of the TNM Staging System
pp. 1408-1409(2)
Author: Harry B. Burke

Despite Positive Studies, Popularity of Chemoprevention Drugs Increasing Slowly
pp. 1410-1412(3)
Author: Sarah L. Zielinski

Money Matters: How Cost-Effectiveness Studies Are Done
pp. 1411-1411(1)
Author: Sarah L. Zielinski

Experts Debate Message Sent by Increased Cancer Survival Rates
pp. 1412-1413(2)
Author: Renee Twombly

What's in a Name: Who Is a Cancer Survivor?
pp. 1414-1415(2)
Author: Renee Twombly

Stat Bite: Number of Cancer Survivors by Sex and Years Since Diagnosis, 2001
pp. 1414-1414(1)

In Brief
pp. 1415-1415(1)
Author: Sarah L. Zielinski

Proposal for Public Archive Draws Support, Criticism
pp. 1416-1416(1)
Author: Kate Travis

Clinical Trial Accrual Efforts: Some Progress Amid Ongoing Debate
pp. 1417-1418(2)
Author: Caroline McNeil

Awards, Appointments, Announcements
pp. 1418-1419(2)

Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
pp. 1420-1425(6)
Authors: Jessica B. O’Connell; Melinda A. Maggard; Clifford Y. Ko

Alkylaniline–Hemoglobin Adducts and Risk of Non–Smoking-Related Bladder Cancer
pp. 1425-1431(7)
Authors: Jinping Gan; Paul L. Skipper; Manuela Gago-Dominguez; Kazuko Arakawa; Ronald K. Ross; Mimi C. Yu; Steven R. Tannenbaum

Factors Contributing to Mammography Failure in Women Aged 40–49 Years
pp. 1432-1440(9)
Authors: Diana S. M. Buist; Peggy L. Porter; Constance Lehman; Stephen H. Taplin; Emily White

A Molecular Genetic and Statistical Approach for the Diagnosis of Dual-Site Cancers
pp. 1441-1446(6)
Authors: Dirk Brinkmann; Andy Ryan; Ayse Ayhan; W. Glen McCluggage; Roger Feakins; Mauro F. Santibanez-Koref; Charles A. Mein; Simon A. Gayther; Ian J. Jacobs

Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder
pp. 1447-1457(11)
Authors: Sameek Roychowdhury; Robert A. Baiocchi; Srinivas Vourganti; Darshna Bhatt; Bradley W. Blaser; Aharon G. Freud; Jason Chou; Chang-Shi Chen; Jim J. Xiao; Mark Parthun; Kenneth K. Chan; Charles F. Eisenbeis; Amy K. Ferketich; Michael R. Grever; Ching-Shih Chen; Michael A. Caligiuri

Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma
pp. 1457-1466(10)
Authors: Magnus Lindskog; Christian Spenger; Jüri Jarvet; Astrid Gräslund; Per Kogner

Mammographic Density and Breast Cancer After Ductal Carcinoma In Situ
pp. 1467-1472(6)
Authors: Laurel A. Habel; James J. Dignam; Stephanie R. Land; Martine Salane; Angela M. Capra; Thomas B. Julian

Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells
pp. 1473-1477(5)
Authors: Daisy W. J. van der Schaft; Richard E. B. Seftor; Elisabeth A. Seftor; Angela R. Hess; Lynn M. Gruman; Dawn A. Kirschmann; Yumi Yokoyama; Arjan W. Griffioen; Mary J. C. Hendrix

Re: Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma
pp. 1478-1479(2)
Authors: Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Herwig Köppel; Hellmut Samonigg

RESPONSE: Re: Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma
pp. 1479-1479(1)
Authors: Tong Sun; Xiaoping Miao; Xuemei Zhang; Dongxin Lin

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
pp. 1480-1481(2)
Author: Fred Saad

Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
pp. 1480-1480(1)
Author: Christopher C. Parker

< previous issue | next issue > | all issues

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A